The The Drug Cell consortium, led by the French Blood Establishment (EFS), GPI, MGA Technologies, and the AFM-Téléthon Stem Cell Research Center, has secured a record-breaking €152 million funding from the European Union.
The goal: to build a modular and scalable cell therapy manufacturing plant in France by 2031.
Bringing together academic and industrial leaders, including Carroucell and EVerZom, this initiative aims to establish a sovereign European production capability, a field still largely dominated by the U.S. and Asia.
As Hervé de Malliard, CEO of MGA Technologies, states: “Our goal is to democratize access to these costly treatments by automating processes and making production viable in Europe.”
A significant leap forward for innovation and European health independence!
In the Same Category
ENVOL Project: Maison MGA at the Heart of the “Organs-on-a-Chip” Revolution
As regulatory and ethical pressures push the industry to move away from animal testing, a major technological breakthrough is emerging in the Auvergne-Rhône-Alpes region. Maison MGA, through its subsidiary MGA MedTech, is partnering with the ENVOL project to bring the...
France2030 initiative : Breaking news
Supported by the French government as part of the France2030 initiative, in collaboration with the Secrétariat général pour l'investissement and the PIIEC Med4Cure, this program is primarily aimed at strengthening France’s health and industrial sovereignty, with a...